Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Dis -- Exploratory study shows clinical improvement in patients with pulmonary arterial hypertension (PAH) -- Current treatment options have limited benefit for this debilitating, rapidly progressive and incurable blood vessel disease --...
Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury Jones KE et al.- Levetiracetam is as effective as phenytoin in preventing early posttraumatic seizures but is associated with an increased seizure tendency on EEG analysis.
--- SEIZURE TOP ARTICLES --- Seminars in Neurology, 07/25...
Researchers to Evaluate a Once-Daily Investigational Dose of Raltegravir, Merck's Integrase Inhibitor, in an I QDMRK Once-Daily Raltegravir Study to be Conducted in 21 Countries Worldwide WHITEHOUSE STATION, N.J., Oct.7 /PRNewswire/ -- Merck & Co., Inc.
today announced that researchers will conduct a clinical trial to evaluate the use of...
Researchers to Evaluate a Once-Daily Investigational Dose of Raltegravir, Merck's Integrase Inhibitor, in an I WHITEHOUSE STATION, N.J., Oct.7 NJ-Merck-HIV QDMRK Once-Daily Raltegravir Study to be Conducted in 21 Countries Worldwide WHITEHOUSE STATION, N.J., Oct.
7 /PRNewswire/ -- Merck & Co., Inc.
today announced that researchers will...
Researchers to Evaluate a Once-Daily Investigational Dose of Raltegravir, Merck's Integrase Inhibitor, in an I QDMRK Once-Daily Raltegravir Study to be Conducted in 21 Countries Worldwide WHITEHOUSE STATION, N.J., Oct.7 /PRNewswire/ -- Merck & Co., Inc.
today announced that researchers will conduct a clinical trial to evaluate the use of...
Pain Management: Important Goal in Treating Cancer Patients Mahay is a clinical oncology/hematology pharmacist at Banner Desert Medical Center in Mesa, Arizona.Cancer pain continues to be a health care problem due to its growing rate and the continuous undertreatment of patients with cancer pain....
Xarelto: new oral anticoagulant Bayers Xarelto (rivaroxaban 10 mg tablets) is the second new oral anticoagulant to be marketed in Canada this year, following the introduction of Boehringer Ingelheims Pradax (dabigatran etexilate 75 mg and 110 mg capsules) in July.Both...
Process for producing solid dosage forms Title: United States Patent: 7,419,685 Inventors: Kothrade; Stephan (Limburgerhof, DE), Berndl; Gunther (Herxheim, DE), Simon; Dirk (Mutterstadt, DE), Sanner; Axel (Frankenthal, DE) Assignee: BASF Aktiengesellschaft (Ludwigshafen, DE) Appl....
FDA posts list of 'problem drugs' The Food & Drug Administration has begun posting a list of medications that are being investigated for potential problems, some of them life-threatening.The first list named 20 medications and the most serious issue associated...
20 Drugs the FDA Is Watching from WebMD a health information Web site for patients September 6, 2008 The FDA is 'evaluating' new adverse-event reports for 20 drugs, the agency announced today.A 2007 federal law requires the FDA to disclose all its investigations into...
Learn about the World CNS Therapeutics Market This report analyzes the worldwide markets for CNS Therapeutics in Millions of US$.The specific product Groups analyzed are Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management (includes Migraine, Nociceptive and neuropathic...
Learn about the World CNS Therapeutics Market CNS THERAPEUTICS MCP-1835 A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level...
Learn about the World CNS Therapeutics Market World CNS Therapeutics Market This report analyzes the worldwide markets for CNS Therapeutics in Millions of US$.The specific product Groups analyzed are Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management (includes...
Learn about the World CNS Therapeutics Market World CNS Therapeutics Market This report analyzes the worldwide markets for CNS Therapeutics in Millions of US$.The specific product Groups analyzed are Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management (includes...
ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased C Efficacy and Tolerability Profile Consistent With Data Seen in Approved Treatment-Experienced Indication WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--ISENTRESS (raltegravir), Merck & Co., Inc.s first-in-class integrase inhibitor, in...
